ONC vs. TAK: BeOne Medicines vs. Takeda Pharmaceutical Stock Comparison

Company Profile

BeOne Medicines (ONC) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while TAK is classified in Pharmaceuticals.

Both BeOne Medicines (ONC) and Takeda Pharmaceutical (TAK) trade as ADRs — their core financials are comparable, but keep FX, depositary-program fees, and dividend withholding in view for each.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. BeOne Medicines (ONC) has a non-negative beta of 0.59.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BeOne Medicines (ONC) at 18.40% sits in the top ROE quartile, while Takeda Pharmaceutical (TAK) at 0.56% is closer to the peer norm — stronger capital efficiency for ONC.

BeOne Medicines (ONC) at 13.86% retains a top-quartile share of revenue as profit, ahead of Takeda Pharmaceutical (TAK) at 0.87%, which keeps about the industry-typical share.

Both BeOne Medicines (ONC) at 22.15% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

BeOne Medicines (ONC) at 40.23% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Takeda Pharmaceutical (TAK) reports EPS growth of 77.96%, ranked against its industry; BeOne Medicines (ONC) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BeOne Medicines (ONC) at 3.55 keeps current ratio within its industry’s typical mid-range, while Takeda Pharmaceutical (TAK) at 1.15 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TAK.

BeOne Medicines (ONC) at 0.35 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

BeOne Medicines (ONC) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; BeOne Medicines (ONC) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Both look expensive on trailing earnings: BeOne Medicines (ONC) at 52.17 sits in the richer P/E ratio quartile, and Takeda Pharmaceutical (TAK) at 300.29 is richer still, above its industry range.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while BeOne Medicines (ONC) at 7.04 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 looks cheap against book in the lower P/B ratio quartile, while BeOne Medicines (ONC) at 7.98 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics